Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Post by WHATTHE1on Sep 20, 2020 11:42am
496 Views
Post# 31588508

Hint? reason why the RS was triggered?

Hint? reason why the RS was triggered?


I think James gave a hint. The webcast was Aug 17th. Within that webcast is a treasure trove of information.

Bring forward Aristotle as an LDT (Laboratory Developed Test) they need to do the Cap and CLIA certification and that will take less than two months.That’s @ 30:30 of the webcast! StageZero operates a CAP and CLIA certified lab!

So if it takes less that two months I think it would be realsitic to say that within the next few weeks we will get a NEW RELEASE on that!

Is this the reason to initiate that RS split? OCT 17th is approx two months. Thats if to say when the webcast was dilevered testing started. It could be before or after as well. Do not really know.

Other nice quotes...

“Simultaneous  screening of 10 cancers!”
 
“develop genderspecific cancer detection panels”
 
“Furthermore, the Company is planning to capitalize on the flexibility
of its SentinelPrinciple® technology platform and expand the applications
of Aristotle™ beyond oncology to help in the diagnosis of disease states
in gastroenterology, neurology, cardiology, autoimmune disease,
heart disease, and psychiatric disorders.”

“According to StageZero, Aristotle™, as potentially the first multiple,
discrete cancer diagnostic test from a single sample of blood, could
realize a $2 billion revenue opportunity.”
 
“Saliva Collection will continue to stay abreast of this situation (@ 7min of webcast)
Will always introduce new testing as appropriate”
 

https://www.webcaster4.com/Webcast/Page/2082/36633


https://www.cap.org/laboratory-improvement/accreditation/laboratory-accreditation-program
 



Do your own DD. Not investment advice at all.

Bullboard Posts